蛋白精氨酸脱亚胺酶 (PAD) 是一组钙依赖性酶,在瓜氨酸化过程中起着至关重要的作用,可以催化精氨酸残基转化为瓜氨酸。该化学反应诱导瓜氨酸化蛋白的形成,导致结构和功能发生改变,从而导致多种病理疾病,包括炎症和自身免疫性疾病。这些病理将 PAD 确立为治疗靶点,并且已知有多种 PAD 抑制剂。
人类编码了五种 PAD,称为 PAD 1-4 和 PAD6。在五种 PAD 同工酶(PAD1、2、3、4 和 6)中,只有四种(PADs1-4)具有催化活性。PAD 活性受 Ca2+ 严格调控,PAD 含有 4 个 (PAD1)、5 个 (PAD3、4) 或 6 个 (PAD2) Ca2+ 结合位点。PAD 活性失调(最显著的是 PAD2 和 PAD4)与多种炎症性疾病(例如类风湿性关节炎)以及癌症有关,而 PAD 抑制剂(例如 Cl-amidine 和 BB-Cl-amidine)在多种临床前动物疾病模型中均显示出疗效。
Protein arginine deiminase (PAD), is a group of calcium-dependent enzymes, which play crucial roles in citrullination, and can catalyze arginine residues into citrulline. his chemical reaction induces citrullinated proteins formation with altered structure and function, leading to numerous pathological diseases, including inflammation and autoimmune diseases. These pathologies established the PADs as therapeutic targets and multiple PAD inhibitors are known.
Humans encode five PADs, designated PADs 1-4 and PAD6. Of the five PAD isozymes (PAD1, 2, 3, 4 and 6), only four (PADs1-4) are catalytically active. PAD activity is tightly regulated by Ca2+ and PADs contain 4 (PAD1), 5 (PAD3, 4) or 6 (PAD2) Ca2+-binding sites. Dysregulated PAD activity, most notably PAD2 and PAD4, is associated with multiple inflammatory diseases (e.g., rheumatoid arthritis) as well as cancer, and PAD inhibitors, such as Cl-amidine and BB-Cl-amidine, show efficacy in multiple preclinical animal models of disease.
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号